KBKabyashree Buragohain

Kabyashree Buragohain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kabyashree Buragohain has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Combating Foodborne Fungal Infections

    by Mayuri Bhagawati, Chayan Dhar, Sukanya Sonowal, Kabyashree Buragohain, Badal Kumar Datta, Ratul Nath

    With new pathogens constantly emerging, foodborne pathogens continue to pose persistent challenges. The impact of fungi, however, remains significantly underestimated. Foodborne fungal diseases represent a significant threat to public health and food safety worldwide, as fungal pathogens and their toxic metabolites can contaminate a wide range of food products. This chapter explores current advancements in the diagnostics and control of foodborne fungal diseases, emphasizing the latest techniques in fungal detection and identification, including molecular diagnostics, rapid assays, and biosensors. Additionally, various control strategies, such as chemical, biological, and environmental approaches, aimed at minimizing fungal contamination in food production and processing are tackled. The chapter also discusses emerging challenges related to fungal resilience, regulatory standards, and the need for innovative, eco-friendly control measures to enhance food safety. By providing insights into diagnostic and preventative methods, this chapter aims to contribute to the development of more effective food safety protocols, helping mitigate the risks associated with foodborne fungal pathogens.

  • l‐Asparaginase Bio‐Betters: Insight Into Current Formulations, Optimization Strategies and Future Bioengineering Frontiers in Anti‐Cancer Drug Development

    by Sukanya Sonowal, Kalyani Pathak, Dibyajyoti Das, Kabyashree Buragohain, Ankita Gogoi, Nikha Borah, Aparoop Das, Ratul Nath

    Cancer remains a persistent global health concern, representing a significant challenge in medical science and patient care. In this context, l‐asparaginase has emerged as a promising therapeutic agent due to its unique ability to deplete circulating asparagine, thereby selectively targeting cancer cells. However, despite its potential, current formulations of l‐asparaginase are not without limitations. Issues such as immunogenicity, short half‐life, and variable efficacy present hurdles in its widespread clinical application. To overcome these hurdles, researchers are focusing on developing bio‐better versions of l‐asparaginase. These bio‐betters aim to enhance stability, reduce immunogenicity, and optimize enzyme kinetics, thus improving treatment outcomes. This review critically assesses the current landscape of l‐asparaginase bio‐betters, offering insights into ongoing formulations and advancements, optimization strategies, and future bio‐engineering frontiers. It discusses modifications to enhance therapeutic properties and explores innovative approaches like in‐silico enzyme engineering and artificial intelligence, highlighting their potential to improve the therapeutic profile of l‐asparaginase. Challenges and debates surrounding the l‐asparaginase mechanism are also addressed. By addressing current challenges and outlining future directions, this review aims to contribute to the advancement of anti‐cancer therapeutics, particularly in the context of l‐asparaginase bio‐better research.